LB Pharmaceuticals Inc Common Stock (LBRX) is a publicly traded the market company. As of May 21, 2026, LBRX trades at $27.83 with a market cap of $795.49M and a P/E ratio of -8.88. LBRX moved +2.86% today. Year to date, LBRX is +36.33%; over the trailing twelve months it is flat. Its 52-week range spans $13.36 to $33.47. Analyst consensus is strong buy with an average price target of $46.00. Rallies surfaces LBRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
LB Pharmaceuticals Raises $100M, Holds $365.6M Cash as It Launches Two Phase Trials: LB Pharmaceuticals has initiated the pivotal Phase 3 NOVA-2 trial in acute schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression, with topline data expected in H2 2027 and Q1 2028 respectively. Following a $100 million private placement, the company holds $365.6 million in cash and marketable securities, funding operations into Q2 2029.
| Metric | Value |
|---|---|
| Price | $27.83 |
| Market Cap | $795.49M |
| P/E Ratio | -8.88 |
| EPS | $-3.13 |
| Dividend Yield | 0.00% |
| 52-Week High | $33.47 |
| 52-Week Low | $13.36 |
| Volume | 36 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-25.20M |
| Gross Margin | 0.00% |
5 analysts cover LBRX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $46.00.